- BioMerieux‘s first-quarter sales reached €1.10 billion, surpassing analyst estimates of €1.08 billion.
- Sales increased by 14% year-over-year.
- Organic sales growth for the quarter was 12.7%.
- The company maintains its forecast for at least 7% organic sales growth for the year 2025.
- BioMerieux confirms its 2025 sales guidance for a minimum of 7% growth at constant scope and exchange rates.
- The company remains confident in achieving at least a 10% increase in CEBIT in 2025 compared to 2024, at constant scope and exchange rates.
- A currency effect is anticipated to negatively impact the 2025 annual CEBIT by approximately €35 million to €40 million, an increase from the previous estimate of €30 million.
- The company is closely monitoring tariff changes, evaluating their financial impact, and considering potential mitigating actions.
- Analyst ratings for BioMerieux include 12 buy recommendations, 3 holds, and 2 sells.
A look at BioMerieux Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Investors looking at BioMerieux for the long term can find optimism in its Smart Scores across various factors. With a Growth score of 3 and a Resilience score of 4, the company shows potential for expansion and stability in the face of challenges. In addition, BioMerieux‘s Momentum score of 5 indicates strong positive performance trends. While Value and Dividend scores are at 2, the overall outlook seems promising based on these scores.
BioMerieux, a company known for designing innovative diagnostic systems for medical and industrial purposes, focuses on detecting infectious diseases and assessing microbiological quality in diverse samples. The company’s dedication to advancing in vitro diagnostics positions it well for future opportunities, supported by its solid Growth, Resilience, and Momentum scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
